ACE Inhibition in Heart Failure and Ischaemic Heart Disease
Author:
Campbell Duncan J. John
Publisher
Springer Netherlands
Reference234 articles.
1. Abbas, A., Gorelik, G., Carbini, L.A., and Scicli, A.G., 1997, Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension, 30: 217–221. 2. Abdulla, J., Abildstrom, S.Z., Christensen, E., Kober, L., and Torp-Pedersen, C., 2004, A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail, 6: 927–935. 3. Abdulla, J., Barlera, S., Latini, R., Kjoller-Hansen, L., Sogaard, P., Christensen, E., Kober, L., and Torp-Pedersen, C., 2007, A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail: (in press). 4. Abuissa, H., Jones, P.G., Marso, S.P., and O’Keefe, J.H., Jr., 2005, Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol, 46: 821–826. 5. Ader, R., Chatterjee, K., Ports, T., Brundage, B., Hiramatsu, B., and Parmley, W., 1980, Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation, 61: 931–937.
|
|